• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4.

作者信息

Manalo E, Merritt T A, Kheiter A, Amirkhanian J, Cochrane C

机构信息

Department of Pediatrics, University of California Davis 95616, USA.

出版信息

Pediatr Res. 1996 Jun;39(6):947-52. doi: 10.1203/00006450-199606000-00004.

DOI:10.1203/00006450-199606000-00004
PMID:8725253
Abstract

The serum components of C-reactive protein, lysophosphati-dylcholine, fibrinogen, and fibrinogen proteolytic products have been shown to reduce surface tension-lowering abilities of lung surfactant. The inhibitory effects of these serum components were compared among four different surfactants: natural lung surfactant, a phospholipid mixture that had no surfactant proteins, KL4 surfactant which has a synthetic surfactant protein B (SP-B)-like peptide, and beractant (BER) which has both SP-B and SP-C. The pulsating bubble surfactometer was used to measure the surface tension of these surfactants after the addition of inhibitors. Inhibition of BER and KL4 surfactant was observed with some serum components within 1 min of pulsation, but was reversed after 3 min of pulsation for KL4 surfactant and to a lesser extent with BER. The surface tension of phospholipid mixture alone was significantly increased and did not improve with further pulsations. Natural lung surfactant was least inhibited and was affected only at very high fibrinogen concentrations (5 mg/mL). At identical concentrations of these inhibitors, KL4 surfactant was inhibited less compared with BER. We conclude that the response of a lung surfactant to inhibitory agents may depend on the presence or absence of surfactant-related protein(s) in the surfactant and the concentration of exogenous surfactant used. KL4 surfactant, which has a synthetic peptide in lieu of SP-B, resists inhibition to these serum components more than BER at similar phospholipid concentrations.

摘要

相似文献

1
Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4.
Pediatr Res. 1996 Jun;39(6):947-52. doi: 10.1203/00006450-199606000-00004.
2
Characterization of surfactant subtypes of beractant and a synthetic peptide containing surfactant KL4 following surface area cycling and addition of fibrinogen.在进行表面积循环以及添加纤维蛋白原后,对贝拉克坦的表面活性剂亚型和含表面活性剂KL4的合成肽进行表征。
Lung. 1997;175(4):225-33. doi: 10.1007/pl00007569.
3
Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro.
Biochemistry. 1990 Sep 11;29(36):8424-9. doi: 10.1021/bi00488a032.
4
Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipid mixture in vitro--comparison to natural surfactant.
Biochim Biophys Acta. 1991 Jan 4;1081(1):45-52. doi: 10.1016/0005-2760(91)90248-g.
5
Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations.血浆蛋白对表面活性剂的抑制作用:各种表面活性剂制剂的差异敏感性。
Eur Respir J. 1993 Jul;6(7):971-7.
6
Synthetic peptide-containing surfactants--evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution.含合成肽的表面活性剂——跨膜螺旋与两亲性螺旋的评估以及表面活性蛋白C的聚缬氨酸到聚亮氨酸取代
Eur J Biochem. 1998 Jul 1;255(1):116-24. doi: 10.1046/j.1432-1327.1998.2550116.x.
7
The influence of pH on surface properties of lung surfactants.pH对肺表面活性剂表面性质的影响。
Lung. 1995;173(4):243-54. doi: 10.1007/BF00181876.
8
Protein composition of synthetic surfactant affects gas exchange in surfactant-deficient rats.合成表面活性剂的蛋白质组成影响表面活性剂缺乏大鼠的气体交换。
Pediatr Res. 1998 May;43(5):666-73. doi: 10.1203/00006450-199805000-00016.
9
[A coagulative type of pulmonary surfactant depletion--a mechanism of damage to the pulmonary surfactant system].[一种凝固型肺表面活性物质耗竭——肺表面活性物质系统损伤的一种机制]
Hokkaido Igaku Zasshi. 1994 May;69(3):434-44.
10
The role of palmitic acid in pulmonary surfactant: enhancement of surface activity and prevention of inhibition by blood proteins.
Biochim Biophys Acta. 1991 Sep 11;1085(2):248-56. doi: 10.1016/0005-2760(91)90101-m.

引用本文的文献

1
Alveolar lipids in pulmonary disease. A review.肺部疾病中的肺泡脂质。综述。
Lipids Health Dis. 2020 Jun 3;19(1):122. doi: 10.1186/s12944-020-01278-8.
2
Radiation Mitigating Properties of Intranasally Administered KL Surfactant in a Murine Model of Radiation-Induced Lung Damage.经鼻给药的KL表面活性剂在辐射诱导的肺损伤小鼠模型中的辐射减轻特性
Radiat Res. 2017 Nov;188(5):491-504. doi: 10.1667/RR14686.1. Epub 2017 Sep 6.
3
Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future.呼吸窘迫综合征表面活性剂治疗的演变:过去、现在与未来。
Pediatr Res. 2017 Jan;81(1-2):240-248. doi: 10.1038/pr.2016.203. Epub 2016 Oct 5.
4
A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.对接受卢西纳可、贝拉克坦或泊拉坦阿尔法治疗的早产儿再次插管导致的住院费用进行的药物经济学分析。
J Pediatr Pharmacol Ther. 2012 Jul;17(3):220-7. doi: 10.5863/1551-6776-17.3.220.
5
Lucinactant: new and approved, but is it an improvement?卢西纳克坦:新获批药物,但它是一种改进吗?
J Pediatr Pharmacol Ther. 2012 Jul;17(3):206-10. doi: 10.5863/1551-6776-17.3.206.
6
Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS.卢西那肽可减轻 RDS 早产羊模型的肺部炎症反应,保护肺结构,并改善生理结局。
Pediatr Res. 2012 Oct;72(4):375-83. doi: 10.1038/pr.2012.96. Epub 2012 Jul 20.
7
An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease.新生儿肺表面活性物质概述:遗传学、代谢以及表面活性物质在健康与疾病中的作用
Mol Genet Metab. 2009 Jun;97(2):95-101. doi: 10.1016/j.ymgme.2009.01.015. Epub 2009 Feb 4.
8
Surfactant therapy for meconium aspiration syndrome: current status.胎粪吸入综合征的表面活性剂治疗:现状
Drugs. 2005;65(18):2569-91. doi: 10.2165/00003495-200565180-00003.
9
The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.重症监护中的肺科医生 - 第9部分:急性呼吸窘迫综合征的非通气策略
Thorax. 2002 Sep;57(9):823-9. doi: 10.1136/thorax.57.9.823.
10
Function and inhibition sensitivity of the N-terminal segment of surfactant protein B (SP-B1-25) in preterm rabbits.表面活性蛋白B的N端片段(SP-B1-25)在早产兔中的功能及抑制敏感性
Thorax. 2001 Nov;56(11):871-6. doi: 10.1136/thorax.56.11.871.